As of 2025-05-18, the Intrinsic Value of Kilitch Drugs (India) Ltd (KILITCH.NS) is 101.34 INR. This KILITCH.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 433.95 INR, the upside of Kilitch Drugs (India) Ltd is -76.60%.
The range of the Intrinsic Value is 73.78 - 149.75 INR
Based on its market price of 433.95 INR and our intrinsic valuation, Kilitch Drugs (India) Ltd (KILITCH.NS) is overvalued by 76.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 73.78 - 149.75 | 101.34 | -76.6% |
| DCF (Growth 10y) | 363.71 - 693.89 | 483.48 | 11.4% |
| DCF (EBITDA 5y) | 404.78 - 1,013.23 | 665.17 | 53.3% |
| DCF (EBITDA 10y) | 672.94 - 1,713.86 | 1,094.59 | 152.2% |
| Fair Value | 303.37 - 303.37 | 303.37 | -30.09% |
| P/E | 170.86 - 305.12 | 227.02 | -47.7% |
| EV/EBITDA | 111.52 - 370.56 | 245.69 | -43.4% |
| EPV | (1.80) - 2.54 | 0.37 | -99.9% |
| DDM - Stable | 63.97 - 144.10 | 104.03 | -76.0% |
| DDM - Multi | 268.99 - 480.80 | 345.93 | -20.3% |
| Market Cap (mil) | 6,977.92 |
| Beta | 0.93 |
| Outstanding shares (mil) | 16.08 |
| Enterprise Value (mil) | 7,248.77 |
| Market risk premium | 8.31% |
| Cost of Equity | 14.43% |
| Cost of Debt | 8.05% |
| WACC | 14.04% |